Home > Boards > Canadian > Medical - Drugs >

BriaCell Therapeutics Corp. (BCTXF)

Add BCTXF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/20/2020 7:21:05 AM - Followers: 6 - Board type: Free - Posts Today: 0


About BriaCell

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based vaccine technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.

In a preliminary Phase I clinical study in metastatic (i.e., Stage IV) breast cancer patients who had failed multiple treatments, Bria-IMT™ treatment significantly reduced the tumor size, without serious side effects. Importantly, the tumor regression was observed in other sites including the lung and even the brain -a difficult site. Impressively, the median lifespan of the patients was substantially longer than that of the comparable trials.

At our laboratory facility in Berkeley, CA, we are planning to expand our pipeline of oncology immunotherapy candidates using our proprietary technology platform.

Using the clinical data from the patients from the clinical studies, we are working to identify the molecular fingerprint of the patients for which the vaccine would be highly effective, and are planning to develop diagnostic testing products to identify this group. By directing the drug to the top-responders, we expect this approach to increase the likelihood of clinical trial success of Bria-IMT™ -to bring hope to thousands of cancer patients with few-to-no treatment options.

The company is currently recruiting its Phase I/IIa trial to further test Bria-IMT™ safety and activity in metastatic breast cancer patients. BriaCell maintains global rights for Bria-IMT™.

Phase I/IIa Clinical Study of Bria-IMT™ in Advanced Breast Cancer

BriaCell is currently recruiting patients to evaluate the safety and activity of Bria-IMT™ in an additional Phase I/IIa study in 25-40 metastatic breast cancer patients who have failed at least one course of treatment.

For the details of the trial, please visit For the details of the trial, please visit https://www.clinicaltrials.gov/ct2/show/NCT03066947

Roll-Over Combination Therapy Study

FDA has approved the roll-over combination study of Bria-IMT™ with pembrolizumab (Keytruda; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy; manufactured by Bristol-Myers Squibb Company) for patients previously treated with BriaVax™ from the ongoing Phase I/IIa Clinical Trial in Advanced Breast Cancer. The study is available for patents on the SV-BR-1-GM Phase I/IIa study who develop progressive disease. These patients will be eligible to roll-over into combination therapy with Keytruda or Yervoy, depending on the type of breast cancer they have.

More information on the roll-over combination study of Bria-IMT™ with either ipilimumab or pembrolizumab will be available on ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03328026)

KEYTRUDA® (pembrolizumab)

Manufactured by Merck & Co., Inc., KEYTRUDA® (pembrolizumab) is a prescription medicine that may treat certain cancers by working with the immune system. It has been approved for the treatment of a number of cancer indications excluding breast cancer.

For more information on pembrolizumab, please see:

About YERVOY® (ipilimumab)

Manufactured by Bristol-Myers Squibb Company, YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable). It is a monoclonal antibody that works to activate the immune system and enabling them to recognize and destroy cancer cells.

For more informations on Ipilimumab, please see:


Clinical Development Timeline – Breast Cancer

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#85   NEWS BriaCell Files Patent Application for Novel Immune subslover 05/20/20 07:21:05 AM
#84   A reverse split: 1/300 CREEP 02/04/20 03:20:54 PM
#83   So this stock went up 19,000% the other Alao 01/31/20 10:33:35 PM
#82   BCTXF: effective Jan. 2,2020 a one for 300 Renee 12/31/19 08:48:37 AM
#81   News - BriaCell Announces Closing of Non-Brokered Priv Golden_Cross 10/15/19 05:54:17 PM
#80   BCTXF Daily Chart Golden_Cross 10/07/19 06:42:25 AM
#79   New out - BriaCell Doses First Patient in Golden_Cross 10/07/19 06:41:22 AM
#78   Good news about a significant event is moving bubbarayjr 09/19/19 12:34:35 PM
#77   All aboard!!! North bound!!! 1hunglo 06/03/19 11:01:19 PM
#76   All aboard!!! Heading north 1hunglo 06/03/19 10:59:03 PM
#75   https://finance.yahoo.com/news/briacell-announces-c-500-000-113000856.html shanak10 02/27/19 08:40:36 AM
#74   https://finance.yahoo.com/news/briacell-announces-c-500-000-113000856.html shanak10 02/26/19 07:15:10 AM
#73   The only clinical stage 2 that is currently 1hunglo 01/06/19 03:35:46 PM
#72   https://www.networknewswire.com/networknewsbreaks/networknewsbreaks-patient-dosi shanak10 10/22/18 01:16:58 PM
#71   https://www.otcmarkets.com/stock/BCTXF/news/NetworkNewsAudio-Announces-Audio-Pre shanak10 10/04/18 09:16:56 AM
#70   https://finance.yahoo.com/news/networknewswire-announces-publication-hope-horizo shanak10 10/03/18 09:31:53 AM
#69   $BCTXF going to dabble in this one, long swing. shanak10 09/18/18 09:49:12 AM
#68   Looking good here! CREEP 06/14/18 12:53:16 AM
#67   BriaCell Publishes Clinical Findings in 2018 American Society CREEP 05/30/18 02:17:47 PM
#66   Budfoxhub - mvwise1 05/23/18 02:23:45 PM
#65   check out the $BCTXF news: BriaCell Provides Highlights budfoxfun 04/18/18 11:54:36 AM
#64   otcqb company here https://www.otcmarkets.com/stock/BCTXF/overview budfoxfun 04/18/18 09:06:35 AM
#63   .113's thin on the ask budfoxfun 04/10/18 12:27:28 PM
#62   “The results to be presented will add to budfoxfun 04/10/18 11:30:52 AM
#61   The poster will describe preliminary findings on safety budfoxfun 04/10/18 11:18:54 AM
#60   BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, budfoxfun 04/10/18 11:18:37 AM
#59   news out! BriaCell to Present Encouraging Clinical Data budfoxfun 04/10/18 09:25:38 AM
#58   Dedicated to enhance the lives of cancer patients budfoxfun 04/10/18 09:09:41 AM
#57   undervalued at these levels budfoxfun 04/10/18 08:34:38 AM
#56   solid otcqb company here https://www.otcmarkets.com/stock/BCTXF/overview budfoxfun 04/10/18 07:46:11 AM
#55   green in power hour! budfoxfun 04/03/18 03:25:52 PM
#54   Trading nicely at the HOD. BCTXF Robertscott 04/03/18 03:20:22 PM
#53   The findings detailed in the paper provide a budfoxfun 04/03/18 02:08:12 PM
#52   The peer-reviewed paper provides evidence for the unique budfoxfun 04/03/18 01:11:40 PM
#51   BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, budfoxfun 04/03/18 12:28:48 PM
#50   The findings detailed in the paper provide a budfoxfun 04/03/18 11:42:28 AM
#49   Very interesting stuff for BCTXF Robertscott 04/03/18 11:08:52 AM
#48   BriaCell’s Lead Product Candidate Mechanism of Action Described budfoxfun 04/03/18 09:45:57 AM
#47   BCTXF - Briacell Investment Summary: CREEP 04/03/18 09:26:42 AM
#46   Dedicated to enhance the lives of cancer patients budfoxfun 04/03/18 09:20:47 AM
#45   Agree, a lot of upside here budfoxfun 04/03/18 09:10:32 AM
#44   Great to see you here on this board CREEP 04/03/18 08:54:44 AM
#43   BCTXF News: BriaCell’s Lead Product Candidate Mechanism of CREEP 04/03/18 08:52:59 AM
#42   .113 thin on the ask budfoxfun 04/03/18 08:52:37 AM
#41   undervalued company at these levels budfoxfun 04/03/18 08:22:25 AM
#40   solid otcqb stock here https://www.otcmarkets.com/stock/BCTXF/overview budfoxfun 04/03/18 08:22:12 AM
#39   Insider Buying: CREEP 03/23/18 11:46:53 AM
#38   Upcoming Milestones: From January 2018 CREEP 03/19/18 05:58:19 PM
#37   Huge volume the last 5 days if you CREEP 03/19/18 04:06:12 PM
#36   BriaCell Appoints Top Social Media Marketing Analyst CREEP 03/14/18 12:24:57 PM
Consent Preferences